Latest Breaking News On - Choosing between cart cell therapy and bispecific antibodies - Page 1 : vimarsana.com

Jesus Berdeja, MD, discusses factors to consider when choosing between CAR T-cell therapy and bispecific antibodies in patients with multiple myeloma.

United statesJesus berdejaMyeloma researchMultiple myeloma researchTennessee oncologyChoosing between cart cell therapy and bispecific antibodiesPatients with multiple myeloma